Clinical trial
Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally…
NCT00292552 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00292552 |
|---|---|
| Title | Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints |
| Official title | A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time |
| Acronym | ECLIPSE |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention type | Other |
| Interventions | Novel endpoint determination |
| Enrollment | 2,747 |
| Start date | Dec 1, 2005 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Feb 16, 2006 |
| Last update posted | Mar 23, 2017 |
| Countries | Bulgaria, Canada, Czechia, Denmark, Netherlands, New Zealand, Norway, Slovenia, Spain, Ukraine, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: